Clinical trials: Microsatellite Stable Metastatic Colorectal Cancer
Metastatic Colorectal Cancer, RAS Mutation
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
A phase II clinical study of Sintilimab (IBI308) combined with Bevacizumab, Oxaliplatin and Capecitabine regimen as first-line treatment in patients with RAS-mutant and microsatellite stable metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable
- Trial name
- NCT04194359
- Testing
- Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer Metastatic
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
This study is being done to look at the safety and response to the combination of two investigational drugs, tremelimumab and durvalumab, when given after radiation therapy for patients with microsatellite stable (MSS) metastatic…
- Trial name
- NCT03007407
- Testing
- durvalumab, Tremelimumab
- Where
- 18 sites in United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Advanced Colorectal Cancer
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
This is a translational, multicentre and multinational study. The aim of this study is to identify new patient stratification tools in microsatellite stable RAS mutant metastatic Colorectal Cancer
- Trial name
- COLOSSUS (NCT03699111)
- Where
- 10 sites in Germany, Ireland and 1 more
- Volunteers
- 29 people
- Sponsor
- Cancer Trials Ireland
Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in…
- Trial name
- NCT05608044
- Testing
- Botensilimab, Balstilimab, Standard of Care
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 234 people
- Sponsor
- Agenus Inc.
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
This phase II trial studies how well nivolumab and metformin work in treating patients with microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous treatment.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer
- Trial name
- NCT03800602
- Testing
- Metformin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Advanced Solid Tumors
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic).
- Trial name
- NCT05719558
- Testing
- ASP1002, Bevacizumab, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 798 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S 531011 + fruquintinib or S 531011 + fruquintinib + pembrolizumab in patients with MSS/pMMR colorectal cancer.
- Trial name
- IGNITE-CRC (NCT07591597)
- Testing
- S-531011, Fruquintinib, Pembrolizumab
- Volunteers
- 68 people
- Sponsor
- National Cancer Center Hospital East
Colorectal Cancer Metastatic, High Immune Infiltrate
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
About 85% of cases of non-metastatic colorectal cancer (CRC) are related to chromosomal instability and have a proficient DNA Mismatch-Repair system (pMMR); which are also called CRC with microsatellite stability (MSS).
- Conditions
- Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
- Trial name
- POCHI (NCT04262687)
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- 88 sites in France
- Volunteers
- 55 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Advanced Rectal Cancer, Liver Metastasis
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
Although patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis.
- Conditions
- Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
- Trial name
- Miracle-1 (NCT05359393)
- Testing
- a combination therapy including tislelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard…
- Trial name
- 379 (NCT03791398)
- Testing
- Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201 375mg
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Brown University
Colorectal Cancer Metastatic
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with…
- Trial name
- NCT05243862
- Testing
- PolyPEPI1018, Atezolizumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Treos Bio Limited
MSS, RAS-mutant Colorectal Cancer
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with…
- Trial name
- NCT03271047
- Testing
- binimetinib, nivolumab, ipilimumab
- Where
- 50 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Metastatic Microsatellite Stable Colorectal Cancer
Nivolumab+Ipilimumab+RT in MSS mCRC
This research is being done to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in people with metastatic microsatellite stable colorectal cancer.
- Trial name
- NCT04575922
- Testing
- Nivolumab, Ipilimumab, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital